340 related articles for article (PubMed ID: 30531039)
1. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
2. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
3. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Zegarra-ChapoƱan R; Sanchez C; Yufra-Picardo VM; Tarazona-Santos E; Ugarte-Gil C; Guio H
Mol Genet Genomic Med; 2022 Aug; 10(8):e1987. PubMed ID: 35751408
[TBL] [Abstract][Full Text] [Related]
4.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Vasquez-Dominguez A; Toledo-Nauto A; Capristano S; Sanchez C; Tarazona-Santos E; Ugarte-Gil C; Guio H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232322
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic polymorphisms of
Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
[TBL] [Abstract][Full Text] [Related]
6. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
8. CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.
Perwitasari DA; Irham LM; Darmawan E; Mulyani UA; Atthobari J
Indian J Tuberc; 2016 Jul; 63(3):139-143. PubMed ID: 27865233
[TBL] [Abstract][Full Text] [Related]
9. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
10. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
12. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.
Yuliwulandari R; Susilowati RW; Wicaksono BD; Viyati K; Prayuni K; Razari I; Kristin E; Syafrizal ; Subagyo ; Sri Diana E; Setiawati S; Ariyani A; Mahasirimongkol S; Yanai H; Mushiroda T; Tokunaga K
J Hum Genet; 2016 Jun; 61(6):533-7. PubMed ID: 26911349
[TBL] [Abstract][Full Text] [Related]
13. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.
Fukino K; Sasaki Y; Hirai S; Nakamura T; Hashimoto M; Yamagishi F; Ueno K
J Toxicol Sci; 2008 May; 33(2):187-95. PubMed ID: 18544910
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Capristano S; Sanchez C; Poterico JA; Tarazona-Santos E; Guio H
Pharmacol Res Perspect; 2024 Jun; 12(3):e1179. PubMed ID: 38666760
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.
Feng FM; Guo M; Chen Y; Li SM; Zhang P; Sun SF; Zhang GS
Genet Mol Res; 2014 Nov; 13(4):9463-71. PubMed ID: 25501156
[TBL] [Abstract][Full Text] [Related]
16. NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Yuliwulandari R; Prayuni K; Susilowati RW; M Sofro AS; Tokunaga K; Shin JG
Pharmacogenomics; 2019 Dec; 20(18):1303-1311. PubMed ID: 31699005
[No Abstract] [Full Text] [Related]
17. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
Tang SW; Lv XZ; Zhang Y; Wu SS; Yang ZR; Xia YY; Tu DH; Deng PY; Ma Y; Chen DF; Zhan SY
J Clin Pharm Ther; 2012 Oct; 37(5):588-93. PubMed ID: 22335459
[TBL] [Abstract][Full Text] [Related]
18. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.
Rana SV; Sharma SK; Ola RP; Kamboj JK; Malik A; Morya RK; Sinha SK
J Clin Pharm Ther; 2014 Feb; 39(1):91-6. PubMed ID: 24188272
[TBL] [Abstract][Full Text] [Related]
19. Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Chan SL; Chua APG; Aminkeng F; Chee CBE; Jin S; Loh M; Gan SH; Wang YT; Brunham LR
PLoS One; 2017; 12(10):e0186200. PubMed ID: 29036176
[TBL] [Abstract][Full Text] [Related]
20. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]